Literature DB >> 26304302

Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.

A Wieland1, D N Frank2, B Harnke3, K Bambha1.   

Abstract

BACKGROUND: The human intestinal microbiota is a key regulator of host metabolic and immune functions and alterations in the microbiome ('dysbiosis') have been implicated in several human diseases. Because of the anatomical links between the intestines and the liver, dysbiosis may also disrupt hepatic function and thereby contribute to the pathogenesis of nonalcoholic fatty liver disease (NAFLD). AIM: To perform a comprehensive review of the medical literature investigating associations between intestinal dysbiosis and NAFLD, with a particular emphasis on studies that characterise the microbiome in NAFLD.
METHODS: We conducted a search of PubMed, Embase, and Web of Science using multiple search terms including: 'NAFLD, NASH, fatty liver, steatohepatitis' combined with 'metagenome, microbiom*, microbiota*, fecal flora, intestinal flora, gut bacteria'. Results were manually reviewed and studies selected based on relevance to intestinal microbiota and NAFLD. We also included studies that addressed potential mechanistic models of pathways linking the dysbiosis to NAFLD.
RESULTS: Nine studies (five human and four animal models) were identified in our search that assessed associations between specific intestinal microbiota composition and NAFLD. We reviewed and summarised the results of additional investigations that more broadly addressed the mechanisms by which the microbiome may impact NAFLD pathogenesis.
CONCLUSIONS: Investigations in humans and animals demonstrate associations between intestinal dysbiosis and NAFLD; however, causality has not been proven and mechanistic links require further delineation. As the field of microbiome research matures in techniques and study design, more detailed insights into NAFLD pathogenesis and its associations with the intestinal microbiota will be elucidated.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26304302     DOI: 10.1111/apt.13376

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  62 in total

1.  Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.

Authors:  Shogo Takahashi; Yuhuan Luo; Suman Ranjit; Cen Xie; Andrew E Libby; David J Orlicky; Alexander Dvornikov; Xiaoxin X Wang; Komuraiah Myakala; Bryce A Jones; Kanchan Bhasin; Dong Wang; James L McManaman; Kristopher W Krausz; Enrico Gratton; Diana Ir; Charles E Robertson; Daniel N Frank; Frank J Gonzalez; Moshe Levi
Journal:  J Biol Chem       Date:  2020-02-19       Impact factor: 5.157

2.  Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p.

Authors:  Amanda Hanson; Ignazio S Piras; Danielle Wilhelmsen; Christopher D Still; Xin Chu; Anthony Petrick; Glenn S Gerhard; Johanna K DiStefano
Journal:  Cytokine       Date:  2019-07-25       Impact factor: 3.861

3.  Effects of Probiotics on Inflammation and Uremic Toxins Among Patients on Dialysis: A Systematic Review and Meta-Analysis.

Authors:  Charat Thongprayoon; Wisit Kaewput; Spencer T Hatch; Tarun Bathini; Konika Sharma; Karn Wijarnpreecha; Patompong Ungprasert; Matthew D'Costa; Michael A Mao; Wisit Cheungpasitporn
Journal:  Dig Dis Sci       Date:  2018-08-11       Impact factor: 3.199

Review 4.  Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives.

Authors:  Juan P Arab; Marco Arrese; Vijay H Shah
Journal:  Hepatol Res       Date:  2020-01-13       Impact factor: 4.288

Review 5.  Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.

Authors:  Junli Ma; Qihang Zhou; Houkai Li
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

6.  Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis.

Authors:  Robert M Wilechansky; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Liver Int       Date:  2019-05-24       Impact factor: 5.828

7.  Effect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease.

Authors:  Youngmi Jung; Inyoung Kim; Mohamed Mannaa; Jinnyun Kim; Sihyung Wang; Inmyoung Park; Jieun Kim; Young-Su Seo
Journal:  Food Sci Biotechnol       Date:  2018-07-12       Impact factor: 2.391

Review 8.  Influence of gut microbiota on the development and progression of nonalcoholic steatohepatitis.

Authors:  Fabiana de Faria Ghetti; Daiane Gonçalves Oliveira; Juliano Machado de Oliveira; Lincoln Eduardo Villela Vieira de Castro Ferreira; Dionéia Evangelista Cesar; Ana Paula Boroni Moreira
Journal:  Eur J Nutr       Date:  2017-09-05       Impact factor: 5.614

Review 9.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

Review 10.  Metabolic aspects of adult patients with nonalcoholic fatty liver disease.

Authors:  Ludovico Abenavoli; Natasa Milic; Laura Di Renzo; Tomislav Preveden; Milica Medić-Stojanoska; Antonino De Lorenzo
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.